The observation in the present study that patients with MT KRAS tumours also had better outcomes when they experienced grade 2+ vs. grade 0/1 skin toxicity, is in line with other reports suggesting that EGFR-related skin toxicity may be a prognostic rather than predictive marker of outcome during therapy[25,27]. The gene discussed is KRAS; the disease is neoplasm.